The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Locally advanced esophageal cancer: Evaluation of prognosis by assessment of the “yp” stage based on the neoadjuvant regimen received.
 
Indika Gunadasa
No Relationships to Disclose
 
Andrew Haydon
No Relationships to Disclose
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; Twist Bioscience; UniQure; Vertex; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Deciphera; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi
 
Yin Li Khu
No Relationships to Disclose
 
Paul Burton
Research Funding - Breath Pearls (Inst); CSIRO (Inst); Gilead Sciences (Inst); Novo-nordisk (Inst)
 
Wendy Brown
Stock and Other Ownership Interests - Ramsay Health Care
Consulting or Advisory Role - Merck, Sharpe, and Dohme; Novo Nordisk; Pfizer
Speakers' Bureau - GORE; Merck, Sharpe, and Dohme; Novo Nordisk
Research Funding - Applied medical (Inst); Avant Diagnostics (Inst); Commonwealth of Australia (Inst); GORE (Inst); Johnson & Johnson (Inst); Medtronic (Inst); Novo Nordisk (Inst)